JP2019526537A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526537A5 JP2019526537A5 JP2019503703A JP2019503703A JP2019526537A5 JP 2019526537 A5 JP2019526537 A5 JP 2019526537A5 JP 2019503703 A JP2019503703 A JP 2019503703A JP 2019503703 A JP2019503703 A JP 2019503703A JP 2019526537 A5 JP2019526537 A5 JP 2019526537A5
- Authority
- JP
- Japan
- Prior art keywords
- human insulin
- zinc complex
- acylated derivative
- group
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 21
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 19
- 239000011701 zinc Substances 0.000 claims 18
- 229910052725 zinc Inorganic materials 0.000 claims 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000006239 protecting group Chemical group 0.000 claims 5
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004185 ester group Chemical group 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000002843 carboxylic acid group Chemical group 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022066071A JP2022095872A (ja) | 2016-08-02 | 2022-04-13 | ヒトインスリンまたはそのアナログのアシル化誘導体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610625257 | 2016-08-02 | ||
| CN201610625257.5 | 2016-08-02 | ||
| CN201610779132 | 2016-08-31 | ||
| CN201610779132.8 | 2016-08-31 | ||
| PCT/CN2017/095377 WO2018024186A1 (zh) | 2016-08-02 | 2017-08-01 | 一种人胰岛素或其类似物的酰化衍生物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022066071A Division JP2022095872A (ja) | 2016-08-02 | 2022-04-13 | ヒトインスリンまたはそのアナログのアシル化誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526537A JP2019526537A (ja) | 2019-09-19 |
| JP2019526537A5 true JP2019526537A5 (OSRAM) | 2020-07-02 |
| JP7432361B2 JP7432361B2 (ja) | 2024-02-16 |
Family
ID=61074099
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503703A Active JP7432361B2 (ja) | 2016-08-02 | 2017-08-01 | ヒトインスリンまたはそのアナログのアシル化誘導体 |
| JP2022066071A Pending JP2022095872A (ja) | 2016-08-02 | 2022-04-13 | ヒトインスリンまたはそのアナログのアシル化誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022066071A Pending JP2022095872A (ja) | 2016-08-02 | 2022-04-13 | ヒトインスリンまたはそのアナログのアシル化誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10815287B2 (OSRAM) |
| EP (1) | EP3495384A4 (OSRAM) |
| JP (2) | JP7432361B2 (OSRAM) |
| CN (2) | CN108463468B (OSRAM) |
| TW (1) | TWI747929B (OSRAM) |
| WO (1) | WO2018024186A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI740099B (zh) * | 2018-02-01 | 2021-09-21 | 大陸商江蘇恒瑞醫藥股份有限公司 | 含人胰島素類似物的醯化衍生物的藥物組合物及其製備方法 |
| AU2019218315A1 (en) | 2018-02-09 | 2020-07-09 | Jiangsu Hengrui Medicine Co., Ltd. | Codon optimized precursor gene and signal peptide gene of human insulin analogue |
| TWI742377B (zh) | 2018-05-24 | 2021-10-11 | 大陸商江蘇恒瑞醫藥股份有限公司 | 一種重組人胰島素或其類似物的前驅物的製備方法 |
| BR112021011050A2 (pt) | 2018-12-11 | 2021-08-31 | Sanofi | Ligante peptídico |
| US20240239862A1 (en) | 2019-12-30 | 2024-07-18 | Gan & Lee Pharmaceuticals Co., Ltd. | Insulin Derivative |
| CN116583531A (zh) * | 2020-11-27 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 一种制备胰岛素或其类似物的酰化衍生物的方法 |
| CN112939771A (zh) * | 2021-01-28 | 2021-06-11 | 宁夏蓝博思化学技术有限公司 | 长链烷基二酸单叔丁酯的制备方法 |
| CN115385843A (zh) | 2021-05-24 | 2022-11-25 | 广东东阳光药业有限公司 | 一种新型的酰化胰岛素类似物 |
| AU2022300061A1 (en) | 2021-06-25 | 2024-02-01 | Gan & Lee Pharmaceuticals Co., Ltd. | Acylated insulin-containing pharmaceutical composition |
| CN118574842A (zh) | 2022-01-28 | 2024-08-30 | 甘李药业股份有限公司 | 酰化胰岛素 |
| CN117756914B (zh) * | 2023-12-15 | 2024-09-03 | 瀚晖制药有限公司 | 依柯胰岛素的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| DE122004000035I2 (de) * | 1993-09-17 | 2009-08-06 | Novo Nordisk As | Acyliertes insulin |
| CN1163574A (zh) * | 1994-11-17 | 1997-10-29 | 伊莱利利公司 | 酰化的胰岛素类似物 |
| US6310038B1 (en) * | 1997-03-20 | 2001-10-30 | Novo Nordisk A/S | Pulmonary insulin crystals |
| WO2003075950A1 (en) * | 2002-03-13 | 2003-09-18 | Novo Nordisk A/S | Minimising body weight gain in insulin treatment |
| PT2107069E (pt) | 2003-08-05 | 2013-04-23 | Novo Nordisk As | Novos derivados de insulina |
| EP2107069B1 (en) * | 2003-08-05 | 2013-01-16 | Novo Nordisk A/S | Novel insulin derivatives |
| EP2505593A1 (en) * | 2005-12-28 | 2012-10-03 | Novo Nordisk A/S | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
| EP2178910B1 (en) | 2007-08-15 | 2014-10-08 | Novo Nordisk A/S | Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids |
| PT2910570T (pt) * | 2008-03-18 | 2017-01-24 | Novo Nordisk As | Análogos de insulina acilados, estabilizados contra proteases |
| US8935928B2 (en) * | 2011-10-10 | 2015-01-20 | Lockheed Martin Corporation | Integrated air-cycle refrigeration and power generation system |
| AU2012350586B2 (en) | 2011-12-15 | 2017-02-02 | Jiangsu Hengrui Medicine Co., Ltd. | Human insulin analogue and acylated derivative thereof |
| CN106496322A (zh) | 2015-09-07 | 2017-03-15 | 江苏恒瑞医药股份有限公司 | 人胰岛素或其类似物的酰化衍生物的制备方法 |
| CA3013623A1 (en) * | 2016-02-05 | 2017-08-10 | Memorial Sloan-Ketering Cancer Center | Methods of differentiating stem cell-derived ectodermal lineage precursors |
-
2017
- 2017-08-01 US US16/320,997 patent/US10815287B2/en active Active
- 2017-08-01 WO PCT/CN2017/095377 patent/WO2018024186A1/zh not_active Ceased
- 2017-08-01 EP EP17836368.5A patent/EP3495384A4/en not_active Withdrawn
- 2017-08-01 CN CN201780005001.7A patent/CN108463468B/zh active Active
- 2017-08-01 CN CN202210131921.6A patent/CN114478747B/zh active Active
- 2017-08-01 TW TW106125882A patent/TWI747929B/zh active
- 2017-08-01 JP JP2019503703A patent/JP7432361B2/ja active Active
-
2022
- 2022-04-13 JP JP2022066071A patent/JP2022095872A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526537A5 (OSRAM) | ||
| JP2022095872A5 (OSRAM) | ||
| JP2012512901A5 (OSRAM) | ||
| JP2011006428A5 (OSRAM) | ||
| RU99106518A (ru) | Glp-1 производные | |
| RU2008143668A (ru) | Производное инсулина | |
| WO2019117274A1 (ja) | ペプチドの製造方法、及び塩基の処理方法 | |
| WO2011080102A3 (en) | Glp-1 analogues and derivatives | |
| JP2013526501A5 (OSRAM) | ||
| JP2015110654A5 (OSRAM) | ||
| RU2009122582A (ru) | Пэг-модифицированный эксендин или аналог эксендина и его композиции и применение | |
| JP2007523881A5 (OSRAM) | ||
| EP3495384A1 (en) | Acylated derivative of human insulin or analogue thereof | |
| KR970042553A (ko) | 캠프토테신 유도체 | |
| RU2008141280A (ru) | Агонисты рецептора нейромедина u и их применение | |
| CA3084688A1 (fr) | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes | |
| JP2008545793A5 (OSRAM) | ||
| NZ599791A (en) | Therapeutic peptides | |
| RU2019109719A (ru) | Конъюгаты полимиксин-альгинатных олигомеров | |
| JP2009532384A5 (OSRAM) | ||
| RU2020108281A (ru) | Новые ацилированные аналоги инсулина и варианты их применения | |
| RU2019109728A (ru) | Конъюгаты бацитрацин-альгинатный олигомер | |
| EP3740227A1 (fr) | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide | |
| JP2014530882A5 (OSRAM) | ||
| JP2013516424A (ja) | シクロスポリン類似体 |